Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics

Journal of Clinical Pharmacology

Volumn 51, Issue 3, 2011, Pages 422-427

  Brainard, Diana M ^a   Friedman, Evan J ^a   Jin, Bo ^a   Breidinger, Sheila A ^a   Tillan, Maria D ^b   Wenning, Larissa A ^a   Stone, Julie A ^a   Chodakewitz, Jeffrey A ^a   Wagner, John A ^a   Iwamoto, Marian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Covance Global Clinical Pharmacology Inc ^*  (United States)

Author keywords

food effect; pharmacokinetics; Raltegravir

Indexed keywords

RALTEGRAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ACTIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; HUMAN; LIPID DIET; LOW FAT DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORNING DOSAGE; NIGHTMARE; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DIETARY FATS; FEMALE; FOOD-DRUG INTERACTIONS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; YOUNG ADULT;

EID: 79952801293     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010367652     Document Type: Article

References (26)

1. UNAIDS - Joint United Nations Programme on HIV/AIDS. Report on the global AIDS epidemic 2008. http://www.unaids. org/en/KnowledgeCentre/HIVData/ GlobalReport/2008/. Accessed January 27, 2009.
2. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA. 2008;300:555-570.
3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - a working group of the Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (November 3, 2008). http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed January 27, 2009.
4. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646-650. (Pubitemid 30070911)
5. Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res. 1999;52:351-369.
6. Esposito D, Craigie R. HIV integrase structure and function. Adv Virus Res. 1999;52:319-333.
7. Isentress (raltegravir) [package insert]. Whitehouse Station, NJ: Merck & Co; May 2008. http://www.fda.gov/medwatch/safety/2008/Oct-PI/Isentress- PPI.pdf. Accessed January 27, 2009.
8. Markowitz M, Morales-Ramirez JO, Nguyen B-Y, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515. (Pubitemid 44885615)
9. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125-133. (Pubitemid 47482607)
10. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009;52:350-6.
11. Grinsztejn B, Nguyen B-Y, Katlama C, et al. Potent efficacy of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus: 24-week data. Abstract presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy 46th Annual Meeting; September 27-30, 2006; San Francisco, Calif.
12. Grinsztejn B, Nguyen BY, Katlama C, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Abstract presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo.
13. Grinsztejn B, Nguyen B-Y, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-1269. (Pubitemid 46553846)
14. FDA/CDER Regulatory Guidance Page. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. http://www.fda.gov/cder/ guidance/5194fnl.htm. Accessed January 27, 2009.
15. Wenning LA, Anderson MS, Petry AS, et al. Raltegravir (RAL) dose proportionality and food effect. Abstract presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy 47th Annual Meeting; September 17-20, 2007; Chicago, Ill.
16. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;857:15-19.
17. Lake-Bakaar GL. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988;109: 471-473.
18. Belitsos PC. Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS. JID. 1992;166:277-284.
19. Wilcox CM. No relationship between gastric pH, small bowel bacterial colonization, and diarrhea in HIV-1 infected patients. Gut. 1999;44:101-105. (Pubitemid 29143288)
20. Merck & Co. Raltegravir advisory committee meeting background package. Rockville, Md: US Food and Drug Administration; 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf.12. Accessed January 27, 2009.
21. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52:4338-4343.
22. Wenning L, Nguyen BY, Sun X, et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients. Abstract presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, La.
23. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother. 2005;55:413-416. (Pubitemid 40542576)
24. Muyingo SK, Walker AS, Reid A, et al. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 2008;48: 468-475.
25. Saez-Llorens X, Violari A, Ndiweni D, et al. Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. Pediatrics. 2008;121:e827-e835.
26. Diabate S, Alary M, Koffi CK. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d'Ivoire. AIDS. 2007;21:1799-1803. (Pubitemid 47237568)